Methylphenidate (MP) is a psychostimulant commonly prescribed for attention deficit hyperactivity disorder (ADHD), and Fluoxetine (FLX) is a Serotonin Selective Reuptake Inhibitor (SSRI) commonly prescribed to treat depression and anxiety disorders. Both are shown to impact neurochemistry and behavior, but little is known about their individual and combined impacts on the endocannabinoid system (ECS). We examined the effects of MP and FLX, both as separate treatments and in combination, on…
